ENANTA PHARMACEUTICALS, INC Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENANTA PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $492.00K.
- ENANTA PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $49.00K.
- ENANTA PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $141.00K, a 50.00% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $94.00K.
- ENANTA PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2025 was $145.00K, a 1.36% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2024 was $147.00K, a 93.34% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2023 was $2.21M, a 89.62% decline from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2022 was $21.26M, a 488.32% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $492.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $49.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $141.00K 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $145.00K 10-K · filed 2025-11-19 | |
| 2024-12-31 | $94.00K 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $147.00K 10-K · filed 2025-11-19 | |
| 2024-06-30 | $28.00K 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $51.00K 10-Q · filed 2025-08-13 | |
| 2023-09-30 | $2.21M 10-K · filed 2025-11-19 | |
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-07 | |
| 2023-03-31 | $882.00K 10-Q · filed 2024-08-07 | |
| 2022-12-31 | $1.13M 10-Q · filed 2024-08-07 | |
| 2022-09-30 | $21.26M 10-K · filed 2024-11-27 | |
| 2022-06-30 | $4.12M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $3.80M 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $10.41M 10-Q · filed 2023-08-08 | |
| 2021-09-30 | $3.61M 10-K · filed 2023-11-22 | |
| 2021-06-30 | $686.00K 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $1.15M 10-Q · filed 2022-08-08 | |
| 2020-12-31 | $833.00K 10-Q · filed 2022-08-08 | |
| 2020-09-30 | $10.48M 10-K · filed 2022-11-23 | |
| 2020-06-30 | $3.23M 10-Q · filed 2021-08-09 | |
| 2020-03-31 | $4.72M 10-Q · filed 2021-08-09 | |
| 2019-12-31 | $2.31M 10-Q · filed 2021-08-09 | |
| 2019-06-30 | $512.00K 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $4.47M 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $1.16M 10-Q · filed 2020-08-10 | |
| 2018-06-30 | $2.99M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $1.77M 10-Q · filed 2019-08-09 | |
| 2017-09-30 | $1.08M 10-K · filed 2019-11-27 | |
| 2016-09-30 | $1.03M 10-K · filed 2018-11-29 | |
| 2015-09-30 | $726.00K 10-K · filed 2017-12-11 | |
| 2014-09-30 | $1.05M 10-K · filed 2016-12-09 | |
| 2013-09-30 | $559.00K 10-K · filed 2015-12-11 | |
| 2012-09-30 | $141.00K 10-K · filed 2014-12-11 | |
| 2011-09-30 | $34.00K 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |